Deferasirox (Exjade®, ICL670) treatment of inadequately chelated β-thalassemia patients from the Middle East:: The ESCALATOR trial.

被引：0
|
作者：
Taher, A
El-Beshlawy, A
Al Jefri, A
El Alfy, M
Al Zir, K
Daar, S
Al-Damanhouri, G
Hadler, D
Krahn, U
机构：
[1] Amer Univ Beirut, Chron Care Ctr, Beirut, Lebanon
[2] Cairo Univ, Cairo, Egypt
[3] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
[4] Ain Shams Univ, Cairo, Egypt
[5] Natl Thalassemia Ctr, Damascus, Syria
[6] Sultan Qaboos Univ, Muscat, Oman
[7] King Abdulaziz Univ Hosp, Jeddah, Saudi Arabia
[8] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3840
引用
收藏
页码：40B / 41B
页数：2
相关论文
共 50 条
  • [1] Plasma LPI in β-thalassemia patients before and after treatment with deferasirox (Exjade®, ICL670).
    Daar, S
    Taher, A
    Pathare, A
    Krahn, U
    Gathmann, I
    Nick, H
    Hadler, D
    BLOOD, 2005, 106 (11) : 758A - 758A
  • [2] Iron parameters in 84 MDS patients enrolled in a deferasirox (Exjade®, ICL670) multicenter trial.
    List, Alan F.
    Esposito, Jason
    Decker, Jodie
    Baer, Maria R.
    Powell, Bayard
    Steensma, David
    Raza, Azra
    Terebelo, Howard
    Maciejewski, Jaroslaw
    Goldberg, Stuart L.
    Paley, Carole
    BLOOD, 2006, 108 (11) : 297B - 297B
  • [3] Deferasirox (ICL670) for the treatment of chronic iron overload in patients with β-thalassemia
    Piraino, B.
    Calabro, A.
    Muscolino, G.
    La Rosa, M.
    Rigoli, L.
    Gallizzi, R.
    Salpietro, D. C.
    ACTA PAEDIATRICA, 2007, 96 : 129 - 129
  • [4] Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis
    Porter, J
    Borgna-Pignatti, C
    Baccarani, M
    Saviano, A
    Abish, S
    Malizia, R
    Nick, H
    Opitz, H
    Rabault, B
    Gathmann, I
    Marks, P
    BLOOD, 2005, 106 (11) : 755A - 756A
  • [5] Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade®, ICL670).
    Cohen, A
    Masera, G
    Zoumbos, N
    Uysal, Z
    Boulet, D
    Watman, N
    Loggetto, S
    Opitz, H
    Gathmann, I
    Alberti, D
    BLOOD, 2005, 106 (11) : 242A - 242A
  • [6] Oral deferasirox (Exjade®, ICL670) is effective, with a clinically manageable safety profile, in pediatric β-thalassemia patients with high iron burden
    Taber, Ali
    Al Jefri, Abdullah
    Elalfy, Mollsen Saleh
    Al Zir, Kusai
    Daar, Shahina
    Damanhouri, Ghazi
    Kriemler-Krahn, Ulrike
    Pfluger, Dietrich
    Hadler, Dominik
    El-Beshlawy, Aural
    BLOOD, 2007, 110 (11) : 817A - 817A
  • [7] Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with β-thalassemia, treated with deferasirox (Exjade®, ICL670)
    Piga, A
    Fischer, R
    Harmatz, P
    St Pierre, TG
    Longo, F
    Fung, E
    Engelhardt, R
    Perrotta, S
    Galanello, R
    Capra, M
    Vichinsky, E
    Janka-Schaub, G
    Masera, G
    Cianciulli, P
    Coates, T
    Janssen, G
    Jeng, M
    Lai, ME
    Salles, G
    Cole, P
    Alberti, D
    Rosenkranz, G
    Opitz, H
    BLOOD, 2005, 106 (11) : 755A - 755A
  • [8] PK/PD profiles during deferasirox (Exjade®, ICL670) treatment are similar in Japanese and Caucasian patients with transfusional iron overload
    Iki, S.
    Urabe, A.
    Hata, T.
    Ohyashiki, K.
    Nakao, S.
    Takatoku, M.
    Ishikawa, T.
    Kato, J.
    Tatsumi, Y.
    Mori, H.
    Tanii, H.
    Taniguchi, J.
    Kondo, M.
    Schran, H.
    Rabault, B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 514 - 514
  • [9] Comparative pharmacokinetic/pharmacodynamic profiles in Japanese and Caucasian patients with transfusional hemosiderosis ReceivingTreatment with deferasirox (Exjade®, ICL670).
    Iki, S.
    Urabe, A.
    Hata, T.
    Ohyashiki, K.
    Nakao, S.
    Takatoku, M.
    Ishikawa, T.
    Kato, J.
    Tatsumi, Y.
    Mori, H.
    Tanii, H.
    Taniguchi, J.
    Kondo, M.
    Schran, H.
    Rabault, B.
    BLOOD, 2006, 108 (11) : 296B - 297B
  • [10] Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670)
    Gattermann, N.
    Schmid, M.
    Vassilieff, D.
    Rose, C.
    Porta, M. G. Dell
    Finelli, C.
    Taylor, K.
    Seymour, J. F.
    Lee, J. W.
    Jakobs, P.
    Domokos, G.
    Hadler, D.
    LEUKEMIA RESEARCH, 2007, 31 : S109 - S110
12345